In this context, Mdivi-1, an inhibitor of Drp1 (Dynamin-related protein 1)-mediated mitochondrial fission, has been shown in several studies to suppress inflammatory activation in immune cells, suggesting its potential as a therapeutic agent in inflammatory and metabolic diseases 11. Here, DNM1L is linked to metabolic disease.